{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T11:17:19Z","timestamp":1648639039695},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T00:00:00Z","timestamp":1371772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s11940-013-0248-3","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T10:36:12Z","timestamp":1371724572000},"page":"583-592","source":"Crossref","is-referenced-by-count":0,"title":["Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation"],"prefix":"10.1007","volume":"15","author":[{"given":"Luca","family":"Testa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Adriano","family":"Latini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azeem","family":"Latib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Oreglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Agnifili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Casavecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Paolo","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Lanotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuele","family":"Pizzocri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Mantica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bedogni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,21]]},"reference":[{"key":"248_CR1","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","year":"2010","unstructured":"The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA). Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines for the management of Atrial fibrillation. Eur Heart J. 2010;31:2369\u2013429. These are the guidelines of the major European societies specifically addressing the topic of atrial fibrillation management.","journal-title":"Eur Heart J"},{"key":"248_CR2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/heart.86.5.516","volume":"86","author":"S Stewart","year":"2001","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew\/Paisley study. Heart. 2001;86:516\u201321.","journal-title":"Heart"},{"key":"248_CR3","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370\u20135.","journal-title":"JAMA"},{"key":"248_CR4","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/eurheartj\/ehm358","volume":"28","author":"P Kirchhof","year":"2007","unstructured":"Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J. 2007;28:2803\u201317.","journal-title":"Eur Heart J"},{"key":"248_CR5","first-page":"285","volume":"47","author":"GY Lip","year":"1997","unstructured":"Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997;47:285\u20139.","journal-title":"Br J Gen Pract"},{"key":"248_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","volume":"114","author":"Y Miyasaka","year":"2006","unstructured":"Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119\u201325.","journal-title":"Circulation"},{"key":"248_CR7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949\u201353.","journal-title":"Eur Heart J"},{"key":"248_CR8","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.amjcard.2009.07.022","volume":"104","author":"GV Naccarelli","year":"2009","unstructured":"Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534\u20139.","journal-title":"Am J Cardiol"},{"key":"248_CR9","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","volume":"110","author":"DM Lloyd-Jones","year":"2004","unstructured":"Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042\u20136.","journal-title":"Circulation"},{"key":"248_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am J Med. 2002;113:359\u201364.","journal-title":"Am J Med"},{"key":"248_CR11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","volume":"349","author":"EM Hylek","year":"2003","unstructured":"Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019\u201326.","journal-title":"N Engl J Med"},{"key":"248_CR12","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/eurheartj\/ehn341","volume":"29","author":"S Knecht","year":"2008","unstructured":"Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29:2125\u201332.","journal-title":"Eur Heart J"},{"key":"248_CR13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857\u201367.","journal-title":"Ann Intern Med"},{"key":"248_CR14","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","volume":"118","author":"SJ Connolly","year":"2008","unstructured":"Connolly SJ, Pogue J, Eikelboom J, et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029\u201337.","journal-title":"Circulation"},{"key":"248_CR15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9343(02)01131-2","volume":"113","author":"DB Matchar","year":"2002","unstructured":"Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113:42\u201351.","journal-title":"Am J Med"},{"key":"248_CR16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J Mant","year":"2007","unstructured":"Mant J, Hobbs FD, Fletcher K, et al. Warfarin vs aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomized controlled trial. Lancet. 2007;370:493\u2013503.","journal-title":"Lancet"},{"key":"248_CR17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903\u201312.","journal-title":"Lancet"},{"key":"248_CR18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1358\/dof.2005.030.09.938760","volume":"30","author":"LA Sorbera","year":"2005","unstructured":"Sorbera LA, Bozzo J, Castaner J. Dabigatran\/dabigatran etexilate. Drugs Fut. 2005;30:877\u201385.","journal-title":"Drugs Fut"},{"key":"248_CR19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","volume":"100","author":"MD Ezekowitz","year":"2007","unstructured":"Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419\u201326.","journal-title":"Am J Cardiol"},{"key":"248_CR20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/CIRCULATIONAHA.108.765776","volume":"118","author":"R Nagarakanti","year":"2008","unstructured":"Nagarakanti R, Ezekowitz MD, Parcham-Azad K, et al. Long-term open label extension of the prevention of embolic and thrombotic events on dabigatran in atrial fibrillation (PETRO-Ex study). Circulation. 2008;118:18.","journal-title":"Circulation"},{"key":"248_CR21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"248_CR22","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","volume":"363","author":"SJ Connolly","year":"2010","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875\u20136. Post-hoc analysis of RE-LY specifically addressing the issue of the trend towards higher risk of myocardial infarction.","journal-title":"N Engl J Med"},{"key":"248_CR23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","volume":"125","author":"SH Hohnloser","year":"2012","unstructured":"Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulatoin Therapy) Trial. Circulation. 2012;125:669\u201376. Conclusive evidences on the risk of myocardial infarction with Dabigatran.","journal-title":"Circulation"},{"key":"248_CR24","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"ES Eerenberg","year":"2011","unstructured":"Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573\u20139.","journal-title":"Circulation"},{"key":"248_CR25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1160\/TH09-03-0196","volume":"103","author":"J Xiang","year":"2010","unstructured":"Xiang J, Hu Y, Zhang J, et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014in elderly Chinese subjects. Thromb Haemost. 2010;103:234\u201341.","journal-title":"Thromb Haemost"},{"key":"248_CR26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u20139. The randomized controlled trial supporting the use of Rivaroxaban instead of VKA.","journal-title":"N Engl J Med"},{"key":"248_CR27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806\u201317. The randomized controlled trial supporting the use of Apixaban instead of VKA.","journal-title":"N Engl J Med"},{"key":"248_CR28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV. The ARISTOTLE Committees and Investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"248_CR29","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/qjmed\/hcs114","volume":"105","author":"L Testa","year":"2012","unstructured":"Testa L, Agnifili M, Latini RA, Mattioli R, Lanotte S, De Marco F, et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM. 2012;105:949\u201357. Systematic review, meta-analysis, and indirect meta-analysis of trials comparing new oral anticoagulants vs warfarin.","journal-title":"QJM"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-013-0248-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-013-0248-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-013-0248-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T23:03:30Z","timestamp":1563231810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-013-0248-3"}},"subtitle":["Update on Prevention of Stroke in Patients with AF"],"short-title":[],"issued":{"date-parts":[[2013,6,21]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1007\/s11940-013-0248-3","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,21]]}}}